Skip to main content

Table 1 Relative contribution of HPV 16/18/31/33/45/52/58 in cases of ICC HPV-positive, by region

From: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

  World Africa Asia Western/ Central Asia Eastern Asia Latin America South America Central America North America Europe Oceania
(n = 8,977) (n = 544) (n = 2,641) (n = 836) (n = 1,805) (n = 3,404) (n = 2,629) (n = 775) (n = 160) (n = 2,058) (n = 170)
  RC % (95%CI) RC % (95%CI) RC % (95%CI) RC % (95%CI) RC % (95%CI) RC % (95%CI) RC % (95%CI) RC % (95%CI) RC % (95%CI) RC % (95%CI) RC % (95%CI)
Combinations of HPV types
9 HPV types* 89.4 (88.8-90.1) 86.9 (83.8-89.7) 91.5 (90.4-92.5) 92.0 (89.9-93.7) 91.3 (89.9-92.6) 88.2 (87.0-89.2) 89.2 (87.9-90.3) 84.6 (81.9-87.1) 95.5 (91.2-98.2) 89.1 (87.7-90.4) 89.4 (83.8-93.6)
16/18 70.8 (69.8-71.7) 70.3 (66.2-74.0) 71.6 (69.8-73.4) 77.5 (74.5-80.3) 68.9 (66.7-71.1) 68.2 (66.6-69.8) 69.4 (67.6-71.1) 64.4 (60.9-67.8) 78.8 (71.6-84.8) 72.8 (70.8-74.7) 78.2 (71.3-84.2)
31/33/45/52/58 18.5 (17.7-19.3) 16.7 (13.7-20.1) 19.8 (18.3-21.3) 14.5 (12.2-17.0) 22.3 (20.4-24.3) 19.8 (18.5-21.2) 19.6 (18.1-21.2) 20.3 (17.5-23.3) 16.9 (11.4-23.6) 16.2 (14.6-17.8) 8.8 (5.0-14.1)
Other Types 10.6 (9.9-11.2) 13.0 (10.3-16.2) 8.5 (7.5-9.6) 8.0 (6.3-10.1) 8.7 (7.4-10.1) 11.8 (10.8-13.0) 10.9 (9.7-12.1) 15.4 (12.9-18.1) 4.6 (1.8-8.8) 10.9 (9.6-12.3) 10.6 (6.4-16.2)
Specific HPV types
16 60.5 (59.5-61.6) 47.7 (43.3-51.9) 60.5 (58.6-62.3) 66.7 (63.3-69.8) 57.6 (55.3-59.9) 59.2 (57.5-70.9) 61.3 (59.4-63.2) 52.0 (48.4-55.6) 71.9 (64.2-78.9) 65.5 (63.4-67.6) 58.6 (51.0-66.3)
18 10.3 (9.6-10.9) 22.6 (19.2-26.4) 11.2 (10.0-12.4) 10.8 (8.9-13.2) 11.3 (9.9-12.9) 9.1 (8.1-10.1) 8.1 (7.1-9.2) 12.5 (10.3-15.1) 6.9 (3.48-11.8) 7.3 (6.2-8.5) 19.9 (14.3-26.8)
31 3.7 (3.3-4.1) 1.9 (0.9-3.4) 3.0 (2.4-3.8) 2.8 (1.6-4.0) 3.2 (2.4-4.1) 4.9 (4.2-5.7) 6.5 (5.6-7.6) 4.3 (3.0-5.9) 3.4 (1.0-7.1) 3.4 (2.7-4.3) 0.7 (0.0-3.2)
33 3.8 (3.4-4.3) 1.5 (0.6-2.9) 3.5 (2.8-4.3) 2.5 (1.6-3.8) 4.0 (3.1-4.9) 3.5 (3.2-4.5) 5.0 (4.3-6.0) 2.9 (1.9-4.4) 3.1 (1.0-7.1) 5.7 (4.7-6.8) 2.1 (0.4-5.1)
45 5.9 (5.4-6.4) 9.9 (7.6-12.8) 5.5 (4.7-6.5) 7.0 (5.4-9.0) 4.9 (3.9-6.0) 6.8 (5.9-7.7) 3.7 (3.0-4.4) 7.5 (5.7-9.6) 5.4 (2.6-10.4) 3.9 (3.1-4.8) 5.5 (2.5-9.8)
52 2.8 (2.5-3.2) 2.6 (1.4-4.3) 3.8 (3.1-4.6) 0.8 (0.3-1.7) 5.3 (4.3-6.4) 2.7 (2.2-3.3) 3.0 (2.4-3.7) 1.6 (0.9-2.9) 2.9 (1.0-7.1) 1.9 (1.4-2.6) 0.6 (0.0-3.2)
58 2.3 (2.0-2.6) 0.7 (0.2-1.9) 3.9 (3.2-4.7) 1.3 (0.7-2.3) 5.0 (4.1-6.2) 2.0 (3.3-2.5) 1.4 (1.0-2.0) 3.9 (2.6-5.5) 1.9 (0.39-5.4) 1.3 (0.9-1.9) 0.0 (0.0-2.2)
6 0.1 (0.1-0.2) 0.0 (0.0-0.7) 0.0 (0.0-0.2) 0.0 (0.0-0.4) 0.1 (0.0-0.3) 0.1 (0.0-0.3) 0.1 (0.0-0.3) 0.0 (0.0-0.5) 0.0 (0.0-2.3) 0.2 (0.0-0.4) 1.8 (0.4-5.1)
11 0.0 (0.0-0.1) 0.0 (0.0-0.7) 0.0 (0.0-0.2) 0.0 (0.0-0.4) 0.1 (0.0-0.3) 0.0 (0.0-0.2) 0.0 (0.0-0.2) 0.0 (0.0-0.5) 0.0 (0.0-2.3) 0.0 (0.0-0.2) 0.0 (0.0-2.2)
  1. "ICC": Invasive cervical cancer; “RC”: Relative Contribution; “95%CI”: 95% Confidence Interval; * ”9 HPV types” includes the ones in nine-valent vaccine: HPV 16/18/31/33/45/52/58/6/11.
  2. Additional information: Available data are from unvaccinated women (pre-vaccination period).
  3. Type specific RC estimations: Numerator = single infections + proportional attribution of multiple types; Denominator = HPV DNA positive cervical cancer cases.